{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:18:31Z","timestamp":1772770711218,"version":"3.50.1"},"reference-count":48,"publisher":"Tsinghua University Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.26599\/1671-5411.2023.04.001","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T07:12:13Z","timestamp":1683529933000},"page":"256-267","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of metoprolol standard dosing pathway in Chinese patients with acute coronary syndrome: a prospective multicenter single-arm interventional study"],"prefix":"10.26599","volume":"20","author":[{"given":"Xiao-Yun","family":"YIN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Mei","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Dong","family":"SHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Ping","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe-Xun","family":"LIAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Bing","family":"SHAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Qi","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Ying","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"ZHENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang","family":"CHENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biao","family":"XU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Xing","family":"SHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Chong","family":"HUANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Cheng","family":"GUO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Sheng","family":"FU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Kai","family":"SHAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan-Dan","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Dai","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11138","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/jama.2022.0358","volume":"327","author":"RA Harrington","year":"2022","unstructured":"RA Harrington. Diagnosis and treatment of acute coronary syndromes: a review. 2022, 327: 662-675.","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/0002-8703(93)90128-V","volume":"125","author":"A Belanger","year":"1993","unstructured":"A Belanger. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. 1993, 125: 1148-1154.","journal-title":"Am Heart J"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e000668","DOI":"10.1161\/JAHA.113.000668","volume":"3","author":"A Ghorbani","year":"2014","unstructured":"A Ghorbani. Long-term cardiovascular risks associated with an elevated heart rate: the Framingham Heart Study. 2014, 3: e000668.","journal-title":"J Am Heart Assoc"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/2047487312452501","volume":"21","author":"Y Murakami","year":"2014","unstructured":"Y Murakami. The association between resting heart rate, cardiovascular disease and mortality: evidence from 112, 680 men and women in 12 cohorts. 2014, 21: 719-726.","journal-title":"Eur J Prev Cardiol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","volume":"372","author":"PG Steg","year":"2008","unstructured":"PG Steg. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. 2008, 372: 817-821.","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrcardio.2016.84","volume":"13","author":"K Fox","year":"2016","unstructured":"K Fox. Heart rate reduction in coronary artery disease and heart failure. 2016, 13: 493-501.","journal-title":"Nat Rev Cardiol"},{"key":"ref7","first-page":"1000150","volume":"2","author":"C Wiemann","year":"2014","unstructured":"C Wiemann. Degree of beta-blockade and outcomes in patients with acute coronary syndrome. 2014, 2: 1000150.","journal-title":"J Cardiovasc Dis Diagn"},{"key":"ref8","first-page":"108","volume":"35","author":"group of Chinese experts on appropriate use of beta-adrenergic receptor blocker in coronary heart disease Consensus","year":"2020","unstructured":"group of Chinese experts on appropriate use of beta-adrenergic receptor blocker in coronary heart disease Consensus. [Chinese expert consensus document on appropriate use of beta-adrenergic receptor blocker in patients with coronary heart disease]. 2020, 35: 108-123.","journal-title":"Chinese Circulation Journal"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ahj.2009.06.023","volume":"158","author":"M Tran","year":"2009","unstructured":"M Tran. Use of beta-blockers and effects on heart rate and blood pressure post-acute coronary syndromes: are we on target?. 2009, 158: 378-385.","journal-title":"Am Heart J"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MJT.0b013e3182068d91","volume":"19","author":"WR Jr Colyer","year":"2012","unstructured":"WR Jr Colyer. Impact of an acute coronary syndrome pathway in achieving target heart rate and utilization of evidence-based doses of beta-blockers. 2012, 19: 397-402.","journal-title":"Am J Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","volume":"27","author":"J Lewis","year":"1985","unstructured":"J Lewis. Beta blockade during and after myocardial infarction: an overview of the randomized trials. 1985, 27: 335-371.","journal-title":"Prog Cardiovasc Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"635","DOI":"10.6061\/clinics\/2016(11)03","volume":"71","author":"EA Roque","year":"2016","unstructured":"EA Roque. Mortality reduction with use of oral beta-blockers in patients with acute coronary syndrome. 2016, 71: 635-638.","journal-title":"Clinics (Sao Paulo)"},{"key":"ref13","first-page":"e78","volume":"61","author":"DD Ascheim","year":"2013","unstructured":"DD Ascheim. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. 2013, 61: e78-e140.","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa601","volume":"42","author":"E Barbato","year":"2021","unstructured":"E Barbato. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. 2021, 42: 1289-1367.","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e031972","DOI":"10.1136\/bmjopen-2019-031972","volume":"9","author":"Y Liu","year":"2019","unstructured":"Y Liu. Impact of metoprolol standard dosing pathway in Chinese patients with acute coronary syndrome: protocol for a multicentre prospective study. 2019, 9: e031972.","journal-title":"BMJ Open"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","volume":"130","author":"RG Brindis","year":"2014","unstructured":"RG Brindis. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. 2014, 130: 2354-2394.","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.amjcard.2016.11.059","volume":"119","author":"AO Oseni","year":"2017","unstructured":"AO Oseni. Relation of higher resting heart rate to risk of cardiovascular versus noncardiovascular death. 2017, 119: 1003-1007.","journal-title":"Am J Cardiol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.1503\/cmaj.150535","volume":"188","author":"X Qi","year":"2016","unstructured":"X Qi. Resting heart rate and all-cause and cardiovascular mortality in the general population: a meta-analysis. 2016, 188: E53-E63.","journal-title":"CMAJ"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.numecd.2017.04.004","volume":"27","author":"B \u00f3\u2019Hartaigh","year":"2017","unstructured":"B \u00f3\u2019Hartaigh. Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality: a systematic review and dose-response meta-analysis of prospective studies. 2017, 27: 504-517.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.amjcard.2016.09.006","volume":"119","author":"NB Schiller","year":"2017","unstructured":"NB Schiller. Causes and predictors of death in patients with coronary heart disease (from the Heart and Soul Study). 2017, 119: 27-34.","journal-title":"Am J Cardiol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e5371","DOI":"10.1097\/MD.0000000000005371","volume":"95","author":"J Xiong","year":"2016","unstructured":"J Xiong. The relationship between heart rate and mortality of patients with acute coronary syndromes in the coronary intervention era: meta-analysis. 2016, 95: e5371.","journal-title":"Medicine (Baltimore)"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1161\/01.CIR.101.22.2557","volume":"101","author":"EW Steyerberg","year":"2000","unstructured":"EW Steyerberg. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. 2000, 101: 2557-2567.","journal-title":"Circulation"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jjcc.2010.05.006","volume":"56","author":"H Koga","year":"2010","unstructured":"H Koga. Heart rate on admission is an independent risk factor for poor cardiac function and in-hospital death after acute myocardial infarction. 2010, 56: 197-203.","journal-title":"J Cardiol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/1755-5922.12031","volume":"31","author":"R Das","year":"2013","unstructured":"R Das. Admission heart rate predicts mortality following primary percutaneous coronary intervention for ST-elevation myocardial infarction: an observational study. 2013, 31: 363-369.","journal-title":"Cardiovasc Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"43F","DOI":"10.1016\/0002-9149(86)90888-X","volume":"57","author":"JK Kjekshus","year":"1986","unstructured":"JK Kjekshus. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. 1986, 57: 43F-49F.","journal-title":"Am J Cardiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1111\/j.1476-5381.2012.01972.x","volume":"166","author":"C Zincarelli","year":"2012","unstructured":"C Zincarelli. Blockade of \u03b2-adrenoceptors restores the GRK2-mediated adrenal \u03b1adrenoceptor-catecholamine production axis in heart failure. 2012, 166: 2430-2440.","journal-title":"Br J Pharmacol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"S Agewall","year":"2018","unstructured":"S Agewall. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). 2018, 39: 119-177.","journal-title":"Eur Heart J"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/ehjcvp\/pvab060","volume":"8","author":"R Latini","year":"2022","unstructured":"R Latini. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). 2022, 8: 291-301.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"828614","DOI":"10.3389\/fcvm.2022.828614","volume":"9","author":"J Liu","year":"2022","unstructured":"J Liu. Association between early oral \u03b2-blocker therapy and in-hospital outcomes in patients with ST-elevation myocardial infarction with mild-moderate heart failure: findings from the CCC-ACS project. 2022, 9: 828614.","journal-title":"Front Cardiovasc Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ahj.2010.06.023","volume":"160","author":"M Cuffe","year":"2010","unstructured":"M Cuffe. Beta-blocker use following myocardial infarction: low prevalence of evidence-based dosing. 2010, 160: 435-442.e1.","journal-title":"Am Heart J"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/CRD.0000000000000197","volume":"26","author":"K Watson","year":"2018","unstructured":"K Watson. Through the decades: \u03b2-blocker use and outcomes in acute coronary syndromes. 2018, 26: 157-166.","journal-title":"Cardiol Rev"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ahj.2015.05.012","volume":"170","author":"J Li","year":"2015","unstructured":"J Li. National assessment of early \u03b2-blocker therapy in patients with acute myocardial infarction in China, 2001\u20132011: the China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)-retrospective AMI study. 2015, 170: 506-515.e1.","journal-title":"Am Heart J"},{"key":"ref33","first-page":"2272","volume":"95","author":"Y Chen","year":"2015","unstructured":"Y Chen. [Effect of pathway training on rest heart rate and the application of \u03b2-blocker in coronary heart disease patients: an open-label, multi-center, prospective study]. 2015, 95: 2272-2276.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref34","first-page":"823","volume":"2","author":"J Herlitz","year":"1981","unstructured":"J Herlitz. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. 1981, 2: 823-827.","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(05)67661-1","volume":"366","author":"YP Chen","year":"2005","unstructured":"YP Chen. Early intravenous then oral metoprolol in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. 2005, 366: 1622-1632.","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/oxfordjournals.eurheartj.a061845","volume":"6","author":"in acute myocardial infarction (MIAMI) Metoprolol","year":"1985","unstructured":"in acute myocardial infarction (MIAMI) Metoprolol. A randomised placebo-controlled international trial. The MIAMI Trial Research Group. 1985, 6: 199-226.","journal-title":"Eur Heart J"},{"key":"ref37","first-page":"57","volume":"2","author":"cases of suspected acute myocardial infarction:ISIS-1 027","year":"1986","unstructured":"cases of suspected acute myocardial infarction:ISIS-1 027. First International Study of Infarct Survival Collaborative Group. 1986, 2: 57-66.","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.288.3.351","volume":"288","author":"CS Coffey","year":"2002","unstructured":"CS Coffey. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. 2002, 288: 351-357.","journal-title":"JAMA"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jacc.2013.05.099","volume":"62","author":"FA Masoudi","year":"2013","unstructured":"FA Masoudi. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. 2013, 62: 1791-1801.","journal-title":"J Am Coll Cardiol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1345\/aph.1C472","volume":"38","author":"RJ Jr Cluxton","year":"2004","unstructured":"RJ Jr Cluxton. Beta-blocker underuse in secondary prevention of myocardial infarction. 2004, 38: 286-293.","journal-title":"Ann Pharmacother"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/0735-1097(94)00552-2","volume":"25","author":"E Lev","year":"1995","unstructured":"E Lev. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. 1995, 25: 1327-1332.","journal-title":"J Am Coll Cardiol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/eurheartj\/ehi705","volume":"27","author":"SZ Abildstr\u00f8m","year":"2006","unstructured":"SZ Abildstr\u00f8m. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. 2006, 27: 1153-1158.","journal-title":"Eur Heart J"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jacc.2015.07.047","volume":"66","author":"M Cuffe","year":"2015","unstructured":"M Cuffe. Effect of beta-blocker dose on survival after acute myocardial infarction. 2015, 66: 1431-1441.","journal-title":"J Am Coll Cardiol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ahj.2016.10.012","volume":"184","author":"RO McCubrey","year":"2017","unstructured":"RO McCubrey. \u03b2-blocker dosage and outcomes after acute coronary syndrome. 2017, 184: 26-36.","journal-title":"Am Heart J"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/S0140-6736(08)60601-7","volume":"371","author":"S Yusuf","year":"2008","unstructured":"S Yusuf. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. 2008, 371: 1839-1847.","journal-title":"Lancet"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0735-1097(02)02379-3","volume":"40","author":"R BeLue","year":"2002","unstructured":"R BeLue. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. 2002, 40: 1589-1595.","journal-title":"J Am Coll Cardiol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2019.02.012","volume":"212","author":"J Liu","year":"2019","unstructured":"J Liu. Performance on management strategies with class I recommendation and a level of evidence among hospitalized patients with non-ST-segment elevation acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS) project. 2019, 212: 80-90.","journal-title":"Am Heart J"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/jamacardio.2022.0117","volume":"7","author":"J Liu","year":"2022","unstructured":"J Liu. Performance of management strategies with class I recommendations among patients hospitalized with ST-segment elevation myocardial infarction in China. 2022, 7: 484-491.","journal-title":"JAMA Cardiol"}],"container-title":["Journal of Geriatric Cardiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T07:12:58Z","timestamp":1683529978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciopen.com\/article\/10.26599\/1671-5411.2023.04.001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.26599\/1671-5411.2023.04.001","relation":{},"ISSN":["1671-5411"],"issn-type":[{"value":"1671-5411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}